David Granville

VCHRI

Dr. Granville brings with him a wealth of experience in research, innovation and commercialization. He is a professor in the Department of Pathology and Laboratory Medicine at the University of British Columbia (UBC). He is also a scholar of the Royal Society of Canada and former Canada Research Chair and Canada Top 40 Under 40 recipient. His recent research has led to the formation of the UBC-spin-off company, viDA Therapeutics of which he is a Founder and Chief Scientific Officer. Dr. Granville previously worked at QLT, where his R&D studies supported the approval of Visudyne® to be used as the first treatment for macular degeneration, the leading cause of blindness in the elderly. In 1999, Visudyne® was approved by the FDA—the largest ophthalmic product release in history.